Transgenomic Reports Second Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Transgenomic (TBIO) Tops Q2 EPS by 11c
August 13, 2015 4:36 PM EDTTransgenomic (NASDAQ: TBIO) reported Q2 EPS of ($0.30), $0.11 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $7 million versus the consensus estimate of $7.1 million.
Transgenomic made solid progress in the second quarter in our ongoing transformation into an advanced technology company primarily focused on commercializing the many applications of our Multiplexed ICE COLD-PCR (MX-ICP) technology, said Paul Kinnon, President and Chief Executive Officer. Importantly, we reported good increases in sales in our strategically important businesses, with overall net sales up four percent year over year, and up 11% after adjusting for our... More
